In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 8 ( 2022-8-18), p. e0272567-
Abstract:
Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis who were treated with GLE/PIB at a single center in Taiwan. Sustained virological response (SVR) and adverse events (AEs) were evaluated. Among the 159 patients, 91 and 68 were treated with GLE/PIB for 8 and 12 weeks, respectively. In the per protocol analysis, both the 8- and 12-week groups achieved 100% SVR (87/87 vs. 64/64); and in the evaluable population analysis, 95.6% (87/91) of the 8-week group and 94.1% (64/68) of the 12-week group achieved SVR. The most commonly reported AEs, which included pruritus (15.4% vs. 26.5%), abdominal discomfort (9.9% vs. 5.9%), and skin rash (5.5% vs. 5.9%), were mild for the 8- and 12-week groups. Two patients in the 8-week group exhibited total bilirubin elevation over three times the upper normal limit. One of these two patients discontinued GLE/PIB treatment after 2 weeks but still achieved SVR. Both 8- and 12-week GLE/PIB treatments are safe and effective for patients of Taiwanese ethnicity with HCV and compensated cirrhosis.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0272567
DOI:
10.1371/journal.pone.0272567.g001
DOI:
10.1371/journal.pone.0272567.g002
DOI:
10.1371/journal.pone.0272567.g003
DOI:
10.1371/journal.pone.0272567.t001
DOI:
10.1371/journal.pone.0272567.t002
DOI:
10.1371/journal.pone.0272567.t003
DOI:
10.1371/journal.pone.0272567.s001
DOI:
10.1371/journal.pone.0272567.s002
DOI:
10.1371/journal.pone.0272567.s003
DOI:
10.1371/journal.pone.0272567.r001
DOI:
10.1371/journal.pone.0272567.r002
DOI:
10.1371/journal.pone.0272567.r003
DOI:
10.1371/journal.pone.0272567.r004
DOI:
10.1371/journal.pone.0272567.r005
DOI:
10.1371/journal.pone.0272567.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Permalink